Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRT and Capecitabine in Neoadjuvant Intrahepatic Cholangiocarcinoma
NCT05265208Phase 2Recruiting
- Sponsor
- Centre Eugène Marquis
- Start
- Feb 2022
- Primary completion
- Sep 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Centre Eugène Marquis. Primary endpoint: Frequency of subjects with adequate surgical margins at 5 years. Started Feb 2022; status: recruiting.
02
Drugs
capecitabine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05265208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265208.